Table 2.

Post-Study CLL Therapy by Treatment Arm: Intent-to-Treat Population

Treatment	Treatment Arm (N = 241)
	OBL-FC (n = 120)		FC (n = 121)
	No.	%	No.	%
Any post-study therapy	73	61	81	67
Fludarabine or cladribine	28	23	32	26
Cyclophosphamide/chlorambucil	34	28	39	32
Rituximab	32	27	33	27
Alemtuzumab	7	6	11	9
Other	18	15	23	19

Abbreviations: CLL, chronic lymphocytic leukemia; OBL-FC, oblimersen plus fludarabine/cyclophosphamide; FC, fludarabine/cyclophosphamide.